Eli Lilly testing whether novel COVID-19 antibody drug can quash outbreaks in nursing homes
Eli Lilly & Co. has started a Phase 3 trial of its experimental antibody-based COVID-19 drug in nursing homes and other long-term care facilities, testing whether the drug reduces the infection rate at facilities where residents or staff have recently tested positive for the new coronavirus. The study involves Eli Lilly driving specially modified RVs to newly infected nursing homes and injecting its COVID-19 drug, code-named LY-CoV555, in volunteers, The Wall Street Journal reports. The company said its drug may get government approval by the end of 2020.
Eli Lilly is already testing its antibody treatment, developed with Canadian biotech AbCellera Biologics, in hospitals on COVID-19 patents with mild and more severe cases. Researchers essentially cloned antibodies from one of the first U.S. patients to recover from COVID-19, hoping those proteins help the immune system fight the virus or prevent it from taking hold. If Eli Lilly's drug or another like it proves safe and effective, public health experts say it might serve as a bridge until a vaccine is available.
Nursing homes have been especially susceptible to deadly COVID-19 outbreaks. The new study, conducted in collaboration with the National Institute of Allergy and Infectious Diseases, seeks to enroll 2,400 test subjects.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Mall World: why are people dreaming about a shopping centre?Under The Radar Thousands of strangers are dreaming about the same thing and no one sure why
-
Why scientists are attempting nuclear fusionThe Explainer Harnessing the reaction that powers the stars could offer a potentially unlimited source of carbon-free energy, and the race is hotting up
-
Codeword: October 27, 2025The Week's daily codeword puzzle
-
Warner Bros. explores sale amid Paramount bidsSpeed Read The media giant, home to HBO and DC Studios, has received interest from multiple buying parties
-
Gold tops $4K per ounce, signaling financial uneaseSpeed Read Investors are worried about President Donald Trump’s trade war
-
Electronic Arts to go private in record $55B dealspeed read The video game giant is behind ‘The Sims’ and ‘Madden NFL’
-
New York court tosses Trump's $500M fraud fineSpeed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in IntelSpeed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to ChinaSpeed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with DisneySpeed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B dealSpeed Read Tesla has signed a deal to get its next-generation chips from Samsung
